A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs PSMA ADC (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Progenics Pharmaceuticals
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 14 Feb 2013 Updated results were presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Progenics Pharmaceutical media release. Results were also briefly summarised in the media release.
- 28 Sep 2012 Results will be presented at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Progenics Pharmaceuticals media release. Results were also briefly summarised in the media release.